^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Ovarian Serous Adenocarcinoma
    Drug:adavosertib (AZD1775) (WEE1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

    Excerpt:
    AZD1775 was administered orally twice per day over 2.5 days per week for up to 2 weeks per 21-day cycle (3 + 3 design)….A patient with BRCA1-mutant papillary serous ovarian cancer had a confirmed PR….
    DOI:
    10.1200/JCO.2014.60.4009